Yeji

$ARWR

ARROWHEAD PHARMACEUTICALS, INC.

Runway:cash-flow +
NasdaqMarket cap: —CIK 0000879407

Upcoming catalysts

0 surfaced

No catalysts surfaced for ARWR yet.

Drug pipeline

ARC-AAT Injection
Alpha-1 Antitrypsin Deficiency
ARO-AAT
Alpha 1-Antitrypsin Deficiency
Plozasiran
Familial Chylomicronemia
ARO-ANG 3 Injection
Homozygous Familial Hypercholesterolemia
ARO-HBV
Hepatitis B
ARO-MMP7 Inhalation Solution
Idiopathic Pulmonary Fibrosis
ARO-DIMERPA
Hyperlipidemia; Mixed
ARO-RAGE
Asthma
ARO-HSD Injection
Non-alcoholic Steatohepatitis
ARO-RAGE Injection
Asthma
ARO-ALK7
Obesity
ARC-521 Injection
Hepatitis B
ARO-APOC3
Severe Hypertriglyceridemia
ARO-ATXN2 Injection
Spinocerebellar Ataxia Type 2
Plozasiran Injection
Hypertriglyceridemia
ARO-ANG3
Dyslipidemias
ARO-ENaC
Cystic Fibrosis, Pulmonary
ARO-AAT Injection
Alpha 1-Antitrypsin Deficiency
Fazisiran Injection
Alpha 1-Antitrypsin Deficiency
ARC-520
Hepatitis B
ARC-520 Injection
Hepatitis B
ARO-SOD1 Injection
Amyotrophic Lateral Sclerosis
ARO-INHBE
Obesity
ARO-DUX4 for Injection
Facio-Scapulo-Humeral Dystrophy
ARO-DM1 Intravenous (IV) Infusion
Myotonic Dystrophy 1
ARO-HIF2
Clear Cell Renal Cell Carcinoma
ARO-MUC5AC
Asthma
zodasiran Injection
Homozygous Familial Hypercholesterolemia
Zodasiran
Homozygous Familial Hypercholesterolemia
ARO-MAPT-SC
Alzheimer Disease
ARO-C3
C3 Glomerulopathy
ARO-CFB
IgA Nephropathy
redemplo

Recent & active trials

NCTDrugPhaseStatusPrimary completion
NCT06880770PlozasiranPhase 3Recruiting2029-03-01
NCT06822790Plozasiran InjectionPhase 3Recruiting2028-07-01
NCT07473843ZodasiranPhase 3Not Yet Recruiting2028-07-01
NCT07241546ARO-RAGEPhase 2Recruiting2027-12-01
NCT06700538ARO-INHBEPhase 2Recruiting2027-09-17
NCT07037771zodasiran InjectionPhase 3Recruiting2027-08-20
NCT07221344ARO-MAPT-SCPhase 2Recruiting2027-06-01
NCT06672445ARO-ATXN2 InjectionPhase 1Recruiting2026-12-01
NCT06138743ARO-DM1 Intravenous (IV) InfusionPhase 2Recruiting2026-12-01
NCT06131983ARO-DUX4 for InjectionPhase 2Recruiting2026-12-01
NCT06937203ARO-ALK7Phase 2Recruiting2026-10-01
NCT06347016Plozasiran InjectionPhase 3Active Not Recruiting2026-06-01
NCT06347003Plozasiran InjectionPhase 3Active Not Recruiting2026-06-01
NCT07223658ARO-DIMERPAPhase 2Recruiting2026-06-01
NCT06347133Plozasiran InjectionPhase 3Active Not Recruiting2026-05-01
NCT05413135ARO-APOC3Phase 2Completed2025-09-22
NCT05083364ARO-C3Phase 2Completed2025-09-10
NCT05537025ARO-MMP7 Inhalation SolutionPhase 2Completed2025-09-05
NCT05276570ARO-RAGEPhase 2Completed2025-04-16
NCT06209177ARO-CFBPhase 1Completed2025-03-31

Recent catalysts

FDA approvalNov 18, 2025· 200d ago· success
$ARWRARROWHEAD PHARMACEUTICALS, INC.
redemplo
“openFDA ORIG (TYPE 1) approval of REDEMPLO — application NDA219947”